Abbott aims to roll out its continuous glucose monitor that also tracks ketone levels for diabetic ketoacidosis by the end of the year.

DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...

Many people start a GLP-1 and think the hard part is over. Diabetes experts say that's not the case. GLP-1 medications have ...

Abbott Laboratories (NYSE:ABT) benefits each time a patient replaces a glucose sensor. Continuous glucose monitoring, or CGM, ...

Clinical evidence from a multicentre pivotal trial across 30 US sites involving 307 adults supported the regulatory clearance.

Clearance expands twiist's precise insulin delivery and personalized automation to the largest population of people treated with insulin, with ...

Continuous glucose monitors can dramatically improve blood sugar control among people with type 2 diabetes who aren’t yet ...

Abbott Laboratories (NYSE:ABT) is one of the top 10 picks in President Trump’s latest stock portfolio. Trump bought $1 ...

One type of stock will reward you no matter which direction the major indexes take, and that's the dividend stock. These companies share the wealth with investors by paying them a specific amount on a ...

South Korea's CGM market reached 57.5 billion won in 2024, with imports holding 92.5% as Daewoong, Huons and i-SENS compete.

Constraining policies to select behavior modules allows reinforcement learning transfer from simulation to real robot swarms.

Vancouver, British Columbia, October 21, 2026 /PRNewswire/ -- Stock Preachers Market Commentary: Entering its third trading day of the week, gr ...